Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy

Hideaki Taniguchi, Yoshiaki Iwasaki, Akiko Fujiwara, Kohsaku Sakaguchi, Akio Moriya, Piao Cheng Yu, Akinobu Takaki, Shin Ichi Fujioka, Hiroyuki Shimomura, Yasushi Shiratori

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Platelet count has been shown to correlate with the hepatic fibrosis stage in chronic hepatitis C (CHC). The aim of the present study was to assess hepatic fibrosis progression or regression of CHC patients by long-term monitoring of the platelet count. Methods: A total of 429 interferon (IFN)-treated CHC patients were studied. Follow-up data on the platelet count were collected every 6 months after IFN therapy. The IFN response was defined as follows: complete responders (CR, n = 121) demonstrating persistent clearance of serum hepatitis C virus (HCV) RNA; biochemical responders (BR, n = 94) demonstrating alanine aminotransferase (ALT) normalization for ≥6 months without eradication of HCV-RNA; and non-responder (NR, n = 214) demonstrating all other patterns. Results: In comparison with the baseline level, mean platelet count increased in the CR group from 0.5 years after IFN therapy (for each point, P <0.01), but significantly decreased in the NR group from 1 year after IFN therapy (for each point, P <0.01). In the BR group, an increase in mean platelet count was observed from 0.5 to 3.5 years following IFN therapy (for each point, P <0.01), followed by a gradual decrease. Conclusion: An increase from baseline values in platelet count was observed, regardless of the presence of HCV-RNA, in both the CR and BR groups, suggesting the importance of ALT normalization in preventing hepatic fibrosis progression in IFN-treated CHC patients.

Original languageEnglish
Pages (from-to)281-287
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume21
Issue number1 PART2
DOIs
Publication statusPublished - 2006

Fingerprint

Chronic Hepatitis C
Platelet Count
Interferons
Fibrosis
Liver
Hepacivirus
RNA
Alanine Transaminase
Therapeutics
Serum

Keywords

  • Fibrosis progression
  • Fibrosis regression
  • Hepatitis C
  • Interferon
  • Platelet count

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. / Taniguchi, Hideaki; Iwasaki, Yoshiaki; Fujiwara, Akiko; Sakaguchi, Kohsaku; Moriya, Akio; Yu, Piao Cheng; Takaki, Akinobu; Fujioka, Shin Ichi; Shimomura, Hiroyuki; Shiratori, Yasushi.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 21, No. 1 PART2, 2006, p. 281-287.

Research output: Contribution to journalArticle

Taniguchi, Hideaki ; Iwasaki, Yoshiaki ; Fujiwara, Akiko ; Sakaguchi, Kohsaku ; Moriya, Akio ; Yu, Piao Cheng ; Takaki, Akinobu ; Fujioka, Shin Ichi ; Shimomura, Hiroyuki ; Shiratori, Yasushi. / Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. In: Journal of Gastroenterology and Hepatology (Australia). 2006 ; Vol. 21, No. 1 PART2. pp. 281-287.
@article{599530ef77634afea9ba818c1996b7dc,
title = "Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy",
abstract = "Background: Platelet count has been shown to correlate with the hepatic fibrosis stage in chronic hepatitis C (CHC). The aim of the present study was to assess hepatic fibrosis progression or regression of CHC patients by long-term monitoring of the platelet count. Methods: A total of 429 interferon (IFN)-treated CHC patients were studied. Follow-up data on the platelet count were collected every 6 months after IFN therapy. The IFN response was defined as follows: complete responders (CR, n = 121) demonstrating persistent clearance of serum hepatitis C virus (HCV) RNA; biochemical responders (BR, n = 94) demonstrating alanine aminotransferase (ALT) normalization for ≥6 months without eradication of HCV-RNA; and non-responder (NR, n = 214) demonstrating all other patterns. Results: In comparison with the baseline level, mean platelet count increased in the CR group from 0.5 years after IFN therapy (for each point, P <0.01), but significantly decreased in the NR group from 1 year after IFN therapy (for each point, P <0.01). In the BR group, an increase in mean platelet count was observed from 0.5 to 3.5 years following IFN therapy (for each point, P <0.01), followed by a gradual decrease. Conclusion: An increase from baseline values in platelet count was observed, regardless of the presence of HCV-RNA, in both the CR and BR groups, suggesting the importance of ALT normalization in preventing hepatic fibrosis progression in IFN-treated CHC patients.",
keywords = "Fibrosis progression, Fibrosis regression, Hepatitis C, Interferon, Platelet count",
author = "Hideaki Taniguchi and Yoshiaki Iwasaki and Akiko Fujiwara and Kohsaku Sakaguchi and Akio Moriya and Yu, {Piao Cheng} and Akinobu Takaki and Fujioka, {Shin Ichi} and Hiroyuki Shimomura and Yasushi Shiratori",
year = "2006",
doi = "10.1111/j.1440-1746.2006.04201.x",
language = "English",
volume = "21",
pages = "281--287",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "1 PART2",

}

TY - JOUR

T1 - Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy

AU - Taniguchi, Hideaki

AU - Iwasaki, Yoshiaki

AU - Fujiwara, Akiko

AU - Sakaguchi, Kohsaku

AU - Moriya, Akio

AU - Yu, Piao Cheng

AU - Takaki, Akinobu

AU - Fujioka, Shin Ichi

AU - Shimomura, Hiroyuki

AU - Shiratori, Yasushi

PY - 2006

Y1 - 2006

N2 - Background: Platelet count has been shown to correlate with the hepatic fibrosis stage in chronic hepatitis C (CHC). The aim of the present study was to assess hepatic fibrosis progression or regression of CHC patients by long-term monitoring of the platelet count. Methods: A total of 429 interferon (IFN)-treated CHC patients were studied. Follow-up data on the platelet count were collected every 6 months after IFN therapy. The IFN response was defined as follows: complete responders (CR, n = 121) demonstrating persistent clearance of serum hepatitis C virus (HCV) RNA; biochemical responders (BR, n = 94) demonstrating alanine aminotransferase (ALT) normalization for ≥6 months without eradication of HCV-RNA; and non-responder (NR, n = 214) demonstrating all other patterns. Results: In comparison with the baseline level, mean platelet count increased in the CR group from 0.5 years after IFN therapy (for each point, P <0.01), but significantly decreased in the NR group from 1 year after IFN therapy (for each point, P <0.01). In the BR group, an increase in mean platelet count was observed from 0.5 to 3.5 years following IFN therapy (for each point, P <0.01), followed by a gradual decrease. Conclusion: An increase from baseline values in platelet count was observed, regardless of the presence of HCV-RNA, in both the CR and BR groups, suggesting the importance of ALT normalization in preventing hepatic fibrosis progression in IFN-treated CHC patients.

AB - Background: Platelet count has been shown to correlate with the hepatic fibrosis stage in chronic hepatitis C (CHC). The aim of the present study was to assess hepatic fibrosis progression or regression of CHC patients by long-term monitoring of the platelet count. Methods: A total of 429 interferon (IFN)-treated CHC patients were studied. Follow-up data on the platelet count were collected every 6 months after IFN therapy. The IFN response was defined as follows: complete responders (CR, n = 121) demonstrating persistent clearance of serum hepatitis C virus (HCV) RNA; biochemical responders (BR, n = 94) demonstrating alanine aminotransferase (ALT) normalization for ≥6 months without eradication of HCV-RNA; and non-responder (NR, n = 214) demonstrating all other patterns. Results: In comparison with the baseline level, mean platelet count increased in the CR group from 0.5 years after IFN therapy (for each point, P <0.01), but significantly decreased in the NR group from 1 year after IFN therapy (for each point, P <0.01). In the BR group, an increase in mean platelet count was observed from 0.5 to 3.5 years following IFN therapy (for each point, P <0.01), followed by a gradual decrease. Conclusion: An increase from baseline values in platelet count was observed, regardless of the presence of HCV-RNA, in both the CR and BR groups, suggesting the importance of ALT normalization in preventing hepatic fibrosis progression in IFN-treated CHC patients.

KW - Fibrosis progression

KW - Fibrosis regression

KW - Hepatitis C

KW - Interferon

KW - Platelet count

UR - http://www.scopus.com/inward/record.url?scp=33645302362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645302362&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2006.04201.x

DO - 10.1111/j.1440-1746.2006.04201.x

M3 - Article

C2 - 16460487

AN - SCOPUS:33645302362

VL - 21

SP - 281

EP - 287

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 1 PART2

ER -